Kornimate/medical-research-clean huggingface dataset:
oral amantadine, iv amantadine and hemodynamic response to laryngoscopy

Conditions: Intubation, Intratracheal

Summary: this study will be undertaken-to evaluate the effect of oral amantadine versus iv amantadine premedication on the hemodynamic response to laryngoscopy ,tracheal intubation and surgical incision and their effect on β-endorphins.

direct laryngoscopy and passage of endotracheal tube through the larynx is a noxious stimulus, which can provoke untoward response in the cardiovascular, respiratory and other physiological systems .amantadine is a non-competitive nmda receptor antagonist, and compared to ketamine, it is well tolerated with fewer side effects (mainly dizziness, sedation, and dry mouth). amantadine's formulation permits the oral route for drug delivery, as well as the iv route. the side-effects profile of amantadine via all routes seems not to be harmful in appropriate dosages.. amantadine has been clinically used as an antiviral drug, for dementia, and in the treatment of parkinson's disease and spasticity. it is a non-competitive nmda receptor antagonist, and compared to ketamine, it is well tolerated with fewer side effects (mainly dizziness, sedation, and dry mouth). amantadine's formulation permits the oral route for drug delivery, as well as the iv route. the side-effects profile of amantadine via all routes seems not to be harmful in appropriate dosages. in the central nervous system, beta-endorphins bind mu-opioid receptors and exert their primary action at presynaptic nerve terminals. however, instead of inhibiting substance p, they exert their analgesic effect by inhibiting the release of gaba, an inhibitory neurotransmitter, resulting in excess production of dopamine. this study will be undertaken-to evaluate the effect of oral amantadine versus iv amantadine premedication on the hemodynamic response to laryngoscopy ,tracheal intubation and surgical incision and their effect on β-endorphins.

Eligibility criteria:
inclusion criteria: * asa i\&ii * the age range 20-55 years scheduled for elective back surgery(laminectomy, discectomy and spinal canal stenosis) exclusion criteria: * patient refusal * patients with asa score iii (with chronic kidney, lungs, gastrointestinal tract, liver, or cardiovascular diseases) * pregnant or breastfeeding women. * allergy to any of the study medications and taking medications that could significantly interact with amantadine (tramadol, atropine, antipsychotic medications) * dm, thyroid disease any endocrine disease * suspected difficult intubation or intubation time more than 30 second.

Keywords: oral amantadine iv amantadine tracheal intubation
profiling the dynamic of binge eating disorder (prody-bed)

Conditions: Binge-Eating Disorder; Emotion Regulation; Executive Dysfunction; Eating Behavior; Depressive Symptoms

Summary: the goal of this observational study is to explore if different and specific profiles can be identified in adults with binge eating disorder (bed) depending on their additional eating pathology, emotion regulation and executive functions. the main questions it aims to answer are: * is there different and specific subgroups of patients with bed according to baseline profiles in emotion regulation, executive function and additional eating pathology (including restriction, chaotic eating, grazing and eating on external cues)? * are subgroups of individuals with bed (based on identified profiles) associated with outcome at end of treatment and follow-up? * what is the trajectories in remission rates of specific symptom dimensions (eating disorder pathology, emotion regulation, executive function, and depressive symptoms) in individuals with bed and is there specific trajectory profiles in these dimensions? * is early changes in specific symptom dimensions (eating pathology, emotion regulation, executive function, or depression) associated with outcome of bed? participants will be asked to fill in questionnaires before treatment as usual, 10 weeks into treatment, at end of treatment and at 6- and 12-month follow-up.

binge eating disorder (bed) is a severe eating disorder characterized by recurrent episodes of binge eating, where control over eating is lost and huge amounts of food are eaten within a short period of time. hence, weight issues are often inevitable and overweight is common, as are social, mental as well as physical problems. the etiology of binge eating disorder is an interplay of neurobiological and environmental factors. overall pathological eating, including grazing, external, emotional or restrictive eating, is associated with binge eating, and so is dysregulation in the reward center, impairment of executive functions and emotion regulation. the investigators suggest that it is possible to identify specific profiles driving binge eating, depending on the severity of these dimensions, and that these profiles might predict the outcome of treatment. the investigators also suggest that early change in general eating pattern, emotion regulation, and depressive symptoms is associated with binge eating outcome. these assumptions will be tested in a sample of adults in treatment for bed at one of three sites using questionnaires before, during and after treatment, incl. 6- and 12-month follow-ups.

Eligibility criteria:
inclusion criteria: * age 18+, * diagnosed with binge eating disorder, * and offered treatment at on of the inclusion sites. exclusion criteria: * severe psychiatric comorbidity (e.g. psychosis, severe developmental disorder, severe cogntive impairement)

Keywords: psychotherapy adults binge eating disorder emotion regulation executive function
application of oe in diagnosis of egc

Conditions: High Risk Population of Gastric Cancer

Summary: the main purpose of this study is to evaluate application value of oe mode 2 in the diagnosis of early gastric cancer the secondary purpose is to evaluate application value of oe mode 1 in differentiating the diagnosis of neoplastic lesions of the gastric mucosa.

gastric cancer is the most prevalent cancer in china，while the detection rate of early gastric cancer is lower than 10%. an effective screening method to improve the detection rate is urgently needed. optical enhancement (oe) mode is an endoscopic mode that uses the principle of grating for electronic staining, which provides a clear picture of the submucosal and superficial mucosal vascular structures. the oe1 mode provides enhanced images of the gastric gland tube and blood vessels, as well as magnification. the oe2 mode is used to identify small chromatic aberrations and to visualize superficial structures in the gastric mucosa. so we designed this randomized controlled trial to discuss effectiveness of oe in the diagnosis of early gastric cancer and we hope to find an effective method to improve the detection rate of early gastric cancer in china.

Eligibility criteria:
inclusion criteria: meet item 1or 2 + any items of 3-7 1. male ≥ 40 years old, female ≥ 50 years old. 2. more than one year since the last gastroscopy. 3. patients from the areas with high incidence of stomach cancer (shandong province, liaoning province, fujian province, gansu province, qinghai province, ningxia province, jilin province, jiangsu province, shanghai). 4. patients with pre-cancerous gastric diseases such as chronic atrophic gastritis, gastric ulcer, gastric polyp, hypertrophic gastritis, pernicious anemia, etc. in the past. 5. first-degree relatives of patients with a family history of gastric cancer. 6. other high-risk life factors for gastric cancer (high salt, pickled diet, smoking, heavy alcohol consumption, etc.) 7. positive serum gastric function tests (gastropanel) include: h. pylori (h.p) antibody （+）, fasting pepsinogen i and ii ratio (pg i/pgii) \ 1.50 pmol/l. exclusion criteria: 1. patients who have undergone invasive treatment such as surgical resection, peg, chemotherapy etc. of either stomach or oesophagus. (except for emr and esd). 2. patients with a confirmed diagnosis of progressive cancer above t2 degreed according to the tmn classification of cancer。 3. patients on anticoagulants that cannot be biopsied. 4. patients who have undergone gastrectomy. 5. patients who have taken ppis or h2 receptor antagonist within two weeks. 6. patients with history of malignant neoplasm; high suspicion of neoplasm; severe cardiac, pulmonary, hepatic or renal insufficiency; severe mental illness and pregnant women. 7. patients who did not signed the consent form.

Keywords: early gastric cancer optical enhancement detection rate
pomegranate juice and metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the effect of pomegranate juice (pj) intake on cardiovascular risks in subject with metabolic syndrome.

the effect of pomegranate juice (pj) intake on cardiovascular risks in subject with metabolic syndrome in shabestar.

Eligibility criteria:
inclusion criteria: * presence of ≥3 of the following diagnostic of mets: * serum tgs of at least 150 mg/dl, * waist circumference of more than 102 cm (40 in) in men and more than 88 cm (35 in) in women, * high-density lipoprotein (hdl) level less than 40 mg/dl in men and less than 50 mg/dl in women, * blood pressure 135/85 mm hg or higher, or * fasting glucose 100 mg/dl or higher exclusion criteria: * liver cirrhosis, * chronic pancreatitis, * gastrointestinal or connective diseases, * kidney stones, or * renal failure, * alcohol consumption, * having an allergy to pomegranate juice, * a change in diet, * the large increase in ldl so that required drug treatment. * use of statins of fibrates, corticosteroids, nitrates, acetyl-salicylic acid or other anti-platelet drugs, oral hypoglycemic drugs, nonsteroidal anti-inflammatory drugs, or drugs interfering with coagulation; * pregnancy or lactation in the past 6 mo, supplementation with vitamins or antioxidants
mri and muscle involvement in patients with mutations in gmppb

Conditions: Limb-girdle Muscular Dystrophy

Summary: limb girdle muscular dystrophies (lgmd) are a very heterogeneous group of muscle disorders characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. lgmd is classified based on its inheritance pattern and genetic cause into more than 31 different types. a new type - type 2t has been found. the genetic cause of type 2t is mutations in guanosine diphosphate (gdp)-mannose pyrophosphorylase b (gmppb). mutations in gmppb can also cause congenital muscular dystrophies (cmd). only 41 patients with mutations in gmppb has been reported. in this study, the investigators examine five new cases with the lgmd phenotype. the primary aim is to examine the muscle involvement using mri.


Eligibility criteria:
inclusion criteria: * persons with genetically verified mutations in gmppb exclusion criteria: * all contraindications for undergoing an mri scan

Keywords: mri lgmd gmppb
comparing otc acne treatment to prescription regimen

Conditions: Acne Vulgaris

Summary: this research is being done to find out the safety and efficacy of two acne creams, effaclar and benzaclin when used twice daily with a topical retinoid. effaclar and benzaclin are fda approved for the treatment of acne.

there are many products on the market to treat facial acne. the medication that this study will be evaluating, benzaclin and retin-a have been approved by the fda and is available by prescription, effaclar is an over the counter product. this study will hopefully recognize a treatment combination that is effective in reducing acne vulgaris in adults 18-50.

Eligibility criteria:
inclusion criteria:males and females ages 18-50, mild to moderate acne vulgaris with \> or equal to 15 inflammatory lesions, \> or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study exclusion criteria:participants who have another skin condition that will interfere with lesion counting or assessments
a multi-center environmental study for the treatment of moderate to severe ocular allergic conjunctivitis

Conditions: Allergic Conjunctivitis (AC)

Summary: this is a phase iii multi-center, double-masked, vehicle-controlled, randomized, parallel group study evaluating the efficacy, safety and tolerability of ebi-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe allergic conjunctivitis (ac) three times daily for 4 weeks. approximately 250 subjects at approximately 8 centers in the us will be screened and enrolled into the study.


Eligibility criteria:
inclusion criteria: * give written informed consent and any authorization required by local law (e.g., protected health information waiver) prior to performing any study procedures; * are ≥18 years of age; * have a positive history of ocular allergies during ragweed pollen season; * have signs and symptoms of allergic conjunctivitis in both eyes; * if female and of child-bearing potential, she must not be pregnant or lactating exclusion criteria: * have signs of ocular infection; * have a known history of alcohol or drug abuse; * have been exposed to an investigational drug or device within 30 days of the study; * have planned surgery (ocular or systemic) during the trial period or within 30 days after
a dietary supplement for early cigarette withdrawal

Conditions: Nicotine Dependence, Cigarettes, With Withdrawal

Summary: the purpose of this study is to determine whether a dietary supplement (ds) is effective in protecting against sad mood during early cigarette withdrawal. this study will also assess whether the dietary supplement will be well tolerated during early cigarette withdrawal.

100 subjects who smoke at least 20 cigarettes per day will come in on two different days, at least one week apart, in a randomized, double blind, within subject, placebo controlled design. on each day subjects will refrain from smoking cigarettes for 8 hours. on one day subjects will take the active ds (taken in two doses, the evening dose is taken at 22:00 of the night before the test day and the morning dose is taken at 8:00 of the test day) and on the other day subjects will take placebo (also taken in two doses at the same time points of the active ds). mood symptoms and symptoms of cigarette withdrawal will be compared across the two different days. measures of mood symptom monitoring will include self report on a scale of 1 to 10, standardized rater questions about mood, and 6 hours into withdrawal, a standardized mood induction will be done with mood assessment. symptoms of cigarette withdrawal will be assessed over the duration of withdrawal with applied standardized rating scales by trained raters. for the first 15 - 30 subjects, on each day, a health assessment of a physical exam and blood work will be completed at the end of the withdrawal period on both test days as well as for the initial assessment appointment.

Eligibility criteria:
inclusion criteria: * males and females * age 18-65 * generally good physical health * not using any illicit substances * smoke on average at least 20 cigarettes/day. exclusion criteria: * recent history of myocardial infarction and / or stroke * active substance abuse except for nicotine and active fluctuant medical conditions. (present and ongoing within 3 months) * score of higher than 7 on the 17- item hamilton depression rating scale * positive results for the pregnancy testing done on the first assessment visit. * a specific allergy to fruit-based ingredient.

Keywords: cigarette withdrawal nicotine
agra before and after liver transplantation

Conditions: Liver Cirrhosis

Summary: the immune system is impaired in liver cirrhotic patients, which is associated with a high risk for bacterial infections and worse outcome. a novel biomarker, acellular growth retardation ability (agra), can predict the development of severe infections in patients with liver cirrhosis and therefore identify patients at risk. it is still unclear, how this biomarker develops after liver transplantation and how valid its predictions are for post-operative infections. therefore, agra will be measured before and after liver transplantation and predictive merit of agra for post-transplant infections will be tested.

cirrhosis-associated immune dysfunction syndrome (caids) is a well-recognized phenomenon. it affects all immune cells as well as the humoral immune system. because of this deficiency patients with liver cirrhosis often suffer from severe infections that can be complicated by sepsis, acute renal or liver failure, and lead to prolonged hospitalization and ultimately to the death of the patient. the humoral immune system is a first-line defence mechanism and consists of cell-free molecules that are partly produced by the liver and target pathogens through opsonisation, growth inhibition and lysis. a cirrhotic liver cannot reach its full protein expression capacity and consequently, quantitative and qualitative changes of complement factors and immunoglobulins have been observed in liver disease patients before. liver transplantation remains the only curative option to treat liver cirrhosis and its extrahepatic manifestations; however due to limited organ supply this option is not applicable in all cases. therefore, liver cirrhosis and its complications (eg. infections) need to be managed by health care professionals, who often lack appropriate tools for risk assessment. to meet this clinical need, a novel biomarker was recently established (acellular growth retardation ability, short agra) that uses the state of the humoral immune system to predict the future occurrence of severe infection in liver disease patients. however, it is still unclear how this biomarker develops after liver transplantation and how valid its predictions are for post-operative infections. therefore, patients scheduled for liver transplantation will be included in the trial. agra measurements before and after the transplant (1, 7, 90 days after the end of antibiotic treatment) will be performed. additionally outcome data regarding severe infections are collected for one year before and after transplantation. the respective organ donors are included as a control group.

Eligibility criteria:
inclusion criteria: * patients between 18-80 years * listed for liver transplantation (for recipients) * liver recipient is included in the study (for donors) * informed consent exclusion criteria: * antibiotic therapy with substances active against e. coli at the scheduled blood sampling
venous congestion and acute renal failure in cardiac surgery postoperative

Conditions: Acute Renal Failure (ARF)

Summary: acute renal failure (arf) is a frequent complication in the postoperative cardiac surgery, and is a major risk factor for mortality in this context. the right ventricular dysfunction post cardiopulmonary bypass (cpb) is also a common complication, close to 100% if one takes into account the transient dysfunction. a recent study showed that right ventricular dysfunction and the ira seemed related, rather on the slope of venous congestion. we wish to study this phenomenon more specifically in particular to offer reliable diagnostic markers of venous congestion.


Eligibility criteria:
inclusion criteria: * age: all major patient * gender: both * subject has signed an informed consent * ira kdigo stage 1 or urine output \ 26.5μmol / l * patient in sinus rhythm at the time of the ultrasound measurements * no diuretic since intervention * absence of circulatory failure (low doses of catecholamines tolerated) * extubated: absence of mechanical ventilation exclusion criteria: * chronic heart failure right * chronic renal failure (gfr \<60) * usual treatment with high dose diuretics (furosemide\> 40mg / day) * endocarditis * emergency surgery (aortic dissection, emergency bypass surgery) / heart surgery d / redux * circulatory support * acfa / electro-paced rhythm * inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...) * topic under judicial protection * topic guardianship or curatorship * pregnancy (women of childbearing age) * breastfeeding

Keywords: renal failure renal insufficiency acute renal failure acute renal injury kidney failure kidney insufficiency acute kidney failure acute kidney injury ventricular dysfunction venous congestion renal function kidney function venous heart failure
ovarian tumor biopsies to study response to treatments

Conditions: Epithelial Ovarian Cancer

Summary: this is a research study to look at differences in tumor tissue from ovarian cancer patients that may help to determine response and resistance to treatments.

ovarian cancer participants will be asked to have two tumor biopsies during the research study. the first biopsy will be done prior to receiving the participants' assigned treatments as a part of their cancer care and the second biopsy will be done about 3-7 days after starting treatment. participants who will undergo neoadjuvant treatment and then surgery, will also have their tumor tissue collected during surgery. participants whose disease worsens while on treatment will also be asked to have an additional, optional tumor biopsy. the tumor tissue samples will be studied to look at certain proteins and enzymes, including enzymes called kinomes, that may be important in determining response and resistance to the treatment that participants will receive as a part of their cancer care.

Eligibility criteria:
inclusion criteria: * age ≥18 years. * histological diagnosis of epithelial ovarian cancer * eastern cooperative oncology group (ecog) performance status ≤2. * life expectancy of greater than 3 months * diagnosis of epithelial ovarian cancer undergoing chemotherapy as part of standard care or a clinical trial or receiving a targeted therapy with a targeted agent * must be agreeable to paired biopsies * must have disease amenable to paired biopsy. * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * any contraindication to biopsy * need for anticoagulation that cannot be interrupted
observational study to investigate the effectiveness and safety of olostar tab in patients with essential hypertension and dyslipidemia

Conditions: Hypertension; Dyslipidemias

Summary: the purpose of this study is to investigate the effectiveness and safety of olostar tab in patients with essential hypertension and dyslipidemia


Eligibility criteria:
inclusion criteria: * male or female ≥ 19 * patients have record of blood pressure (sbp/dbp) and ldl-c after prescription of olostar tab. exclusion criteria: * patients that have participated clinical trials or pms with olostar tab.
intracranial aneurysms treatment with the optima coil system

Conditions: Intracranial Aneurysm

Summary: international, non-randomized, european , multicenter, observational study to collect data for the treatment of intracranial aneurysms with optima coils system to further document its safety and efficacy


Eligibility criteria:
inclusion criteria: 1. patient with small or large intracranial aneurysm, ruptured or unruptured, intended to be selectively treated with the optima coil system. patients with recanalized aneurysms previously treated with coils exclusively are also eligible. balloon and stent assisted coiling are allowed at index procedure. 2. in case of multiple aneurysms, patient can be included when only 1 aneurysm is treated during the procedure and none of the other aneurysms are treated up to 30 days post-procedure 3. patient older than 18 years 4. patient who has been informed of the study and has signed an informed consent form where applicable according to local regulations. exclusion criteria: -